Clinical Trial and Research Programs

Our clinical research and trial program was started in 1998 with the goal  of providing our patients with the most cutting edge urological care. We have since conducted over 500 industry and federally funded studies.  

Our office has played a pivotal role in the development of multiple medications including Eligard, Levaquin, Levitra, Vesicare, Detrol, Ditropan XL,Toviaz, and Myrbetriq. We are integrally involved in all the new Castration Resistant Prostate Cancer drugs, such as Provenge (cancer vaccine), 2nd generation oral agents such as Xtandi and Zytiga, to chemotherapy Docetaxel and Cabazitaxel. We continued to work newer agents such as Galetrone and Apalutamide as well as a new agent for bladder cancer.

Our research center is a true center of excellence making new treatments and medication to available to our  patients in the Inland Empire  that otherwise are available only at National Cancer Center Network hospitals such as City of Hope, UCLA or USC, Johns Hopkins, Sloan Kettering Memorial, MD Anderson Medical Center.

Below are some areas of our research interest:

1. Prostate Cancer:  
2. Castration Resistent Prostate Cancer:  
3. Prostate Cancer Prevention 
4. Bladder Cancer & Bladder Cancer Prevention 
5. Overactive Bladder:  
6. Erectile Dysfunction: 
7. Urinary Tract Infection: 
8. Interstitial Cystitis  (Elmiron) and Chronic Pelvic Pain syndrome 
9. BPH 
10. Testosterone replacement therapy 

The following is a list of active reseach protocols at this moment:

1. Enzulutadie Strive Trial, Open label extention mCRCAP patients (Medivation)

2. Apalutamide Spartan Trial, nmCRCAP patients (Jenssen)

2a. Apalutamide for mHSCAP patients (Jenssen)

2b. Apalutamide for Radiation patients (Jenssen)

3. ProstaVac Study for mCRCAP patients (BNIT)

4. ARMOR2 trials mCRCAP patients (Tokai)

4a. ARMOR3-SV for AR-V7 postive mCRCAP patients (Tokai)

5. SoluMatrix Abiraterone Trial for mCRCAP patients (Churchill)

6. Vicinium Bladder cancer and CIS trials (Viventia)

7 Cabazitaxel in mCRCAP patients who fialed Abiraterone (Sanofi).